Cheung Katherine, Brodie Maxwell, Chang Sue-Ling, Deschamps Pierre, Fallu Jean-Sébastien, Farzin Houman, Hébert Johanne, Stephan Jean-François, Dorval Michel, Joly Yann
National Institutes of Health, Bethesda, United States.
McGill University Centre of Genomics and Policy, Montreal, Canada.
J Law Med Ethics. 2025 Jul 31;53(2):1-9. doi: 10.1017/jme.2025.10109.
Psychedelic treatment with psilocybin is receiving increased attention following clinical trials showing it may help treat end-of-life anxiety, depression, and several other conditions. Despite this, physicians may be reluctant to prescribe psilocybin and carry out psilocybin treatment because of the stigma surrounding psychedelics and the potential for medical malpractice liability. This paper explores whether psilocybin treatment gives rise to a risk of medical malpractice liability for physicians. Following an overview of psilocybin treatment and its regulatory regime in Canada, exploratory vignettes are used to highlight the relevance and limits of malpractice claims. This paper argues that the lack of established medical standards, standardized training, and credentialing contribute to liability risks surrounding psilocybin treatment. More clinical trials, meta-studies of research analyses, and knowledge sharing will help to develop training programs and medical standards of practice to better realize psilocybin's potential.
临床试验表明，用裸盖菇素进行迷幻治疗可能有助于治疗临终焦虑、抑郁症和其他几种病症，这使得该疗法越来越受到关注。尽管如此，由于围绕迷幻药的污名以及医疗事故责任风险，医生可能不愿开裸盖菇素处方并实施裸盖菇素治疗。本文探讨裸盖菇素治疗是否会给医生带来医疗事故责任风险。在概述了加拿大的裸盖菇素治疗及其监管制度之后，通过探索性案例来突出医疗事故索赔的相关性和局限性。本文认为，缺乏既定的医疗标准、标准化培训和资质认证加剧了裸盖菇素治疗的责任风险。更多的临床试验、研究分析的荟萃研究以及知识共享将有助于制定培训计划和医疗实践标准，以更好地实现裸盖菇素的潜力。
